Protection against persistence of hepatitis C

Lancet

Volumn 359, Issue 9316, 2002, Pages 1478-1483

  Mehta, Shruti H ^a   Cox, Andrea ^b   Hoover, Donald R ^c   Wang, Xiao Hong ^b   Mao, Qing ^b,e   Ray, Stuart ^b   Strathdee, Steffanie A ^a   Vlahov, David ^d   Thomas, David L ^a,b,f  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d NEW YORK ACADEMY OF MEDICINE   (United States)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; VACCINE;

ADULT; ARTICLE; BEHAVIOR; BODY BURDEN; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SCREENING; DRUG USE; FEMALE; HAZARD ASSESSMENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INCIDENCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROTECTION; RISK; RNA ANALYSIS; TIME; VIREMIA; VIRUS IMMUNITY;

EID: 0037181727     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08435-0     Document Type: Article

References (26)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp
3. Hepatitis C: Global prevalence
4. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
5. Clinical outcomes after transfusion-associated hepatitis C
6. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group
7. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
8. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children: Taiwan Childhood Hepatoma Study Group
9. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
10. Lack of protective immunity against reinfection with hepatitis C virus
11. Immunity in hepatitis C infection
12. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children
13. Hepatitis C virus reinfection after an intravenous drug injection
14. Two successive hepatitis C virus infections in an intravenous drug user
15. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV
16. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection
17. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: Description of methods and characteristics of participants
18. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland
19. Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques
20. Genetic epidemiology of hepatitis C virus throughout Egypt
21. Histological grading and staging of chronic hepatitis
22. Detection of specific sequences among DNA fragments separated by gel electrophoresis
23. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
24. The natural history of hepatitis C virus infection: Host, viral, and environmental factors
25. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses
26. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C